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Abstract
Somatic mutations or loss of expression of tumor suppressor VHL happen in the vast majority of clear cell Renal Cell
Carcinoma, and it’s causal for kidney cancer development. Without VHL, constitutively active transcription factor HIF
is strongly oncogenic and is essential for tumor growth. However, the contribution of individual HIF-responsive genes
to tumor growth is not well understood. In this study we examined the contribution of important HIF-responsive genes
such as VEGF, CCND1, ANGPTL4, EGLN3, ENO2, GLUT1 and IGFBP3 to tumor growth in a xenograft model using
immune-compromised nude mice. We found that the suppression of VEGF or CCND1 impaired tumor growth,
suggesting that they are tumor-promoting genes. We further discovered that the lack of ANGPTL4, EGLN3 or ENO2
expression did not change tumor growth. Surprisingly, depletion of GLUT1 or IGFBP3 significantly increased tumor
growth, suggesting that they have tumor-inhibitory functions. Depletion of IGFBP3 did not lead to obvious activation
of IGFIR. Unexpectedly, the depletion of IGFIR protein led to significant increase of IGFBP3 at both the protein and
mRNA levels. Concomitantly, the tumor growth was greatly impaired, suggesting that IGFBP3 might suppress tumor
growth in an IGFIR-independent manner. In summary, although the overall transcriptional activity of HIF is strongly
tumor-promoting, the expression of each individual HIF-responsive gene could either enhance, reduce or do nothing
to the kidney cancer tumor growth.
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Introduction
The vast majority of renal cell carcinoma (RCC) cases are of
the clear cell type. It is now known that the inactivation of the
VHL tumor suppressor gene plays a causal role in the
pathogenesis of clear cell renal cell carcinomas (ccRCC). In
sporadic ccRCC tumors, about 70% of them harbor biallelic
inactivation of VHL through mutation, deletion, or
hypermethylation of promoter that leads to the loss of its
expression [1]. In hereditary kidney cancer patients, the
inherited germline mutation in one allele of VHL predisposes
them to earlier onset bilateral kidney cancer. The protein
product of VHL tumor suppressor protein, pVHL, is the
substrate recognition unit of an E3 ubiquitin ligase complex that
also contains Cul2, Elongin C and B, and Rbx1[2]. This
complex targets the alpha subunits of the heterodimeric
transcription factor HIF (Hypoxia-Inducible Factor) for
ubiquitylation and destruction. There are three alpha subunits
of HIF and for the simplicity they are referred to as HIFα. Under
normoxia (normal oxygen tension), prolyl hydroxylase modifies
HIFα on key proline residues (Pro) [3-5], which serve as a
binding signal to the beta domain of pVHL. pVHL-containing
complex then promotes ubiquitylation on HIFα, which leads to
quick proteasomal degradation. Hypoxia (oxygen deprivation)
or other pathological conditions prevents prolyl hydroxylation,
and HIFα accumulates and forms complex with HIF1β. HIF
complex binds to Hypoxic response element (HRE) and
regulates transcription of HIF-responsive genes. Increased HIF
activity as a result of VHL inactivation increases the expression
of many genes and contributes to renal carcinoma growth.
Notably, one of the genes whose expression is increased
following VHL inactivation is VEGF, and VEGF and its receptor
VEGFR are confirmed drug targets in ccRCC [6].
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Kidney cancer treatment and drug-resistance
Sunitinib (Sutent®) is a small molecule inhibitor of the
receptor tyrosine kinases of the VEGF family [7], and it[8][9] is
now the front-line standard of care in metastatic RCC. Other
VEGFR inhibitors, such as sorafenib [10], axitinib [11] and
pazopanib [12] were all reported to be active against ccRCC.
However, about 20-30% of the patients do not respond to
VEGFR inhibitor therapies and nearly all will become resistant
[9]. These patients are in urgent need of new and effective
therapies, and identifying new drug targets is a prerequisite
step.
Other HRGs other than VEGF are important for efficient
tumor growth
The relative importance of constitutively active HIF pathway
in kidney cancer initiation and maintenance has been well
established in xenograft models [13,14]. Down-regulation of
HIF2α expression in VHL-/- kidney cancer cells did not inhibit
cellular growth under standard cell culture condition. However,
it severely impaired these cells’ ability to form tumors in a
xenograft model [15]. The transcriptional activity of the HIF2α
was shown to be critical for its oncogenic activity [16,17],
suggesting that the HIF-responsive genes were largely
responsible for its ability to promote tumor growth. Consistent
with this, Mxi-1, a c-Myc antagonist, was found to possess
oncogenic activity [18]. Similarly, Oct4, a transcriptional factor
essential for maintaining stem cell pluripotency [19], TGF-α, an
agonist for EGFR [20], and Ror2, a receptor tyrosine kinase
[21,22], were all shown to be induced by HIF2α and promoted
tumor growth of kidney cancer cells. However, in addition to
them, HIF regulates many aspects of cell biology such as cell
cycle progression, metabolism and glucose homeostasis, and
cell signaling. The contributions to tumor growth by HRGs
involved in these processes were not fully explored, so in this
study we studied the contributions to tumor growth by seven
HRGs. We found that some HRGs enhanced tumor growth,
some did nothing, while some were tumor-suppressive.
Materials and Methods
Cell culture
786-O kidney cancer cells with or without pCDNA3 based
wild type HA-VHL were previously described [15]. The VHL
status and the HIF activity were confirmed by anti-HA and anti-
GLUT1 immunoblots. All the cell lines were maintained in
glutamine-containing DMEM medium supplemented with 10%
Fetal Bovine Serum (FBS) and 1% penicillin and streptomycin.
For hypoxia mimetic treatment, either 200μM Deferoxamine
(DFO, an iron chelator) or 20μM Cobalt Chloride (CoCl2, which
replaces iron at the active site of the prolyl hydroxylases) was
added to the cell culture media for twelve hours. The cells were
washed and lysed for further analysis.
Western Blot analysis
The cells were washed before being lysed with EBC buffer
(50 mM Tris (pH 8), 120 mM NaCl, 0.5% NP-40). A protein
assay kit (500-0006) from Bio-rad was used to determine the
protein concentrations of the lysates. Samples with the same
amount of total protein were boiled with sample buffer before
being resolved by SDS-PAGE and analyzed with standard
western blot techniques. The blots were developed with either
Super Signal Pico substrate (Pierce Biotechnology, Rockford,
IL) or Immobilon Western substrate (Millipore, Billerica, MA).
Antibody against HIF1611079)waspurchased
fromBDtransductionlaboratories (part of BD Biosciences, San
Jose, CA). Antibodies against phopho-tyrosine PY-100 (9411),
actin (4968), IGFIRβ (3018), and anti-Cyclin D1 antibody
(2926) were from Cell Signaling Technology (Boston, MA).
Anti-GLUT1 antibody (NB300-666) and anti-HIF2α
(NB100-132) antibodies were purchased from Novus
Biologicals (Littleton, CO). Anti-IGFBP3 (AF-675) was from
R&D Systems (Minneapolis, MN). Antibodies against PARP1
(sc-7150), GAPDH (sc-59540) and Vinculin (sc-73614) were
from Santa Cruz Biotechnology (Dallas, TX).
Short Hairpin RNAs (shRNAs)
shRNA constructs were obtained from Sigma. The
sequences were listed in Table 1.
Plasmids
Prolines 405 and 531 on pBabe-Puro-HA-tagged HIF2α-dPA
were mutated to Alanines to escape VHL recognition. To
destruct the transcriptional activity of the stabilized HIF2α,
Table 1.
Name of shRNA constructs shRNA sequences
HIF1b-1770 GAGAAGTCAGATGGTTTATTT
HIF2a-1631 CGACCTGAAGATTGAAGTGAT
HIF2a-566 CCATGAGGAGATTCGTGAGAA
VEGF-1137 AGGGCAGAATCATCACGAAGT
VEGF-1500 GCGCAAGAAATCCCGGTATAA
VEGF-1587 GACGTGTAAATGTTCCTGCAA
CCND1-326 GCCCTCGGTGTCCTACTTCAA
CCND1-539 CTCTAAGATGAAGGAGACCAT
CCND1-2322 GCCAGGATGATAAGTTCCTTT
ANGPTL4-786 GCAGAGTGGACTATTTGAAAT
ANGPTL4-1311 GAAGCTTAAGAAGGGAATCTT
EGLN3-692 GTGGCTTGCTATCCGGGAAAT
ENO2-1992 CGCCTGGCTAATAAGGCTTTA
ENO2-1735 CGCACTTTCCACTTCTTCCTT
GLUT1-1598 CCAAAGTGATAAGACACCCGA
GLUT1-455 GCGGAATTCAATGCTGATGAT
GLUT1-2310 GCCACACTATTACCATGAGAA
IGFBP3-633 CCTCCATTCAAAGATAATCAT
IGFBP3-681 CCAGCGCTACAAAGTTGACTA
IGFBP3-711 GAGCACAGATACCCAGAACTT
IGFBP3-770 GCCGTAGAGAAATGGAAGACA
IGFIR-532 GCGGTGTCCAATAACTACATT
IGFIR-1959 CGGCAACCTGAGTTACTACAT
IGFIR-3475 GCCGAAGATTTCACAGTCAAA
IGFIR-2427 GCCTTTCACATTGTACCGCAT
doi: 10.1371/journal.pone.0080544.t001
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Proline 405 on pBabe-Puro-HA-tagged HIF2α-PA-dTA was
mutated to Alanine, the amino acid residues 24-29 RCRRSK
were mutated to ACAASA in the basic helix-loop-helix domain
which would disrupt DNA binding, and the N-terminal and C-
terminal transactivation domains (amino acid residues 450-572
and 820-870) were deleted.
VEGF ELISA
Protein concentration of VEGF was measured by an Elisa kit
(Human VEGF Quantikine ELISA kit; R&D Systems) according
to the manufacturer’s instruction. Briefly, 200μl of standard,
control or sample was added to each well and incubated for 2
hours. After three washes, 200μl of VEGF conjugate was
added for a further 2 hours. After washing, 200μl of substrate
solution was added to each well. After twenty minutes
incubation, the reaction was stopped with 50μl stop solution
and the absorbance was read at 450 nm. The experiments
were performed in duplicates.
Real-time RT-PCR
Total RNA was extracted from cells with Trizol reagent
(Invitrogen) following the instructions from the manufacturer.
RNA concentration was determined by absorbance at 260nm.
A First-strand cDNA Synthesis kit was used to generate First-
strand cDNA (Origene). qRT-PCR was performed using the
7500HT Fast Real-time PCR System (Applied Biosystems) or
with RT2 Real-Time™ ROX PCR Master Mix from
SABiosciences. Genes were amplified using the primers
described in Table S1. All quantifications were normalized to β-
actin.
In vitro proliferation assays
In vitro cell proliferation assays were performed using a Cell
Proliferation Kit II (XTT) from Roche Diagnostics following the
manufacturer's instructions.
Nude mouse xenograft assays and statistical analysis
All animal works were performed with strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institute of Health. The
protocol was approved by a Cleveland Clinic Institutional
Animal Care and Use Committee (ARC 08850). The mice were
anesthetized with isoflurane before subcutaneous injection of
cancer cells, and all efforts were made to minimize pain and
suffering. Subcutaneous nude mice xenograft assays were
performed as previously described [13]. 107 viable cells of a
cell line were injected subcutaneously into one flank of a nude
mouse, and the same number of cells of another cell line was
injected into another flank of the same nude mouse. For each
comparison ten mice were injected in two batches. The mice
were sacrificed 8 to 10 weeks after injection, and tumors were
excised and weighed. Results are presented as mean ±
standard error of the mean. Results were evaluated statistically
using Mann-Whitney U statistic analysis or t-test from
SigmaPlot.
Results
A functional HIF is essential for tumor growth by VHL-
deficient kidney cancer cells
The transcriptional factor Hypoxia Inducible Factor (HIF) is
constituted of two subunits: the labile HIFα and the stable
HIFβ. pVHL targets HIFα for degradation, so HIFα protein
stabilizes and becomes constitutively active in VHL-defective
ccRCC cancer cells [2]. The absence of VHL, which leads to
high level of HIF2α, did not affect the cell growth rates in petri
dishes (Figure S1A in File S1). However, high-level expression
of HIF2α protein has been shown to be necessary and
sufficient for 786-O ccRCC cancer cells to grow into tumors in
orthotopic and subcutaneous xenograft mouse models
[13,15-17,23]. To reconfirm the importance of HIF to tumor
growth in a xenograft model, the expression of HIF1β protein in
786-O cells was stably suppressed by an shRNA construct
HIF1b-1770 (Figure 1A). Suppression of HIF1β’s expression in
786-O cells also eliminated the expression of GLUT1, a marker
of HIF’s transcriptional activity (Figure S2 in File S1). As
expected, the inhibition of HIF1β expression significantly
impaired the tumor growth by 786-O cells when compared to
the same cells carrying an shRNA construct expressing a
control sequence that does not target any known gene (SCR)
(Figure 1B and C). Consistent with the previously reported
importance of HIF2α to tumor growth [15], suppression of the
other HIF subunit, HIF2α, also decreased GLUT1 expression
and significantly impaired the tumor growth (Figure 1D, E and
F).
Validation of HIF-target genes in 786-O cells
In order to examine the relative contributions of individual
HIF-responsive genes (HRG) to the tumor growth, we wished
to validate the HRGs that are tightly regulated by HIF’s
transcriptional activity in 786-O cells before choosing the
targets among them. In VHL-/- cells, the expression of a HRG
should be significantly reduced after HIF2α expression is
suppressed by shRNA. In VHL+/+ cells (where HA-VHL was
stably expressed in the VHL-/- cells), HRG’s expression should
be significantly enhanced by a stable and functional HIF2α
mutant but not by an inactive one. We confirmed that two
independent HIF2α shRNA constructs significantly reduced
HIF2α mRNA in VHL-/- cells, and the VHL+/+ cells with stably
integrated plasmids expressing HIF2a-dPA (active) and the
HIF2a-PA-dTA (inactive) mutants greatly increased the total
HIF2α mRNA levels (Figure 2A).
Next the total RNA was extracted from these cells and real-
time PCR analysis was performed to analyze the expressions
of potentially interesting HRGs previously identified through
microarray analysis. Many genes were confirmed to be bono
fide HRGs that are tightly regulated by HIF’s transcriptional
activity (Figure 2B and Figure S3 in File S1) while some were
not robustly induced by HIF (data not shown). Among the many
validated HRGs, we decided to further analyze the
contributions to tumor growth by VEGF, Cyclin D1 (CCND1),
ENOLASE2 (ENO2), EGLN3, ANGPTL4, GLUT1, and IGFBP3,
because they are involved in many well-known aspects of HIF
biology but their roles were not directly investigated in a ccRCC
Contributions of HIF Target Genes to Kidney Cancer
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xenograft model. VEGF and VEGF receptors are the most
important targets in current clinical treatment of RCC [6].
ANGPTL4 is thought to play critical roles in cancer growth and
progression, angiogenesis, and metastasis[24]. Cyclin D1 is a
very important cell cycle regulator and is reported to be
oncogenic in breast cancer [25], and it was also reported to be
a faithful target of HIF2α that might play an important role in
kidney cancer [26]. ENO2 converts 2-phospho-D-glycerate into
phosphoenolpyruvate and is a key component of the glycolytic
pathway that is critical to ENO1-deficient glioblastoma cancer
cells [27]. EGLN3 is one of the most induced HRGs that could
hydroxylate the most critical proline residues on the HIFα
proteins and have HIF-independent targets [28-31]. GLUT1 is a
key glucose transporter that imports glucose into cancer cells
[32]. IGFBP3 is an important regulator of Insulin-like growth
factor pathway [33].
VEGF and Cyclin D1 both positively contribute to tumor
growth
VEGF is a potent pro-angiogenic factor that is critical for
tumor-induced neo-angiogenesis and the current frontline anti-
cancer drugs such as sunitinib, pazopanib and sorafinib all
Figure 1.  HIF is essential to tumor growth by VHL-deficient RCC cells.  A. Total cell lysates of human renal carcinoma 786-O
cells stably expressing the control shRNA (SCR) or the HIF1b-1770 were prepared and immunoblotted with the indicated
antibodies. B. 786-O VHL-/- cells infected to produce SCR or HIF1b-1770 were injected subcutaneously into the flanks of nude
mice. Approximately 8-10 weeks later, tumors were excised and weighed. Thirteen tumors per line were analyzed. Error bars =
standard error of the mean. P<=0.001 according to a Mann-Whitney U statistic analysis. C. Representative photographs of tumors
analyzed in Figure 1B. Left: Tumor from cells expressing SCR; Right: Tumor from cells expressing HIF1b-1770. D. Total cell lysates
of 786-O cells stably expressing the SCR or the HIF2a-566 were immunoblotted with the indicated antibodies. E. 786-O VHL-/- cells
infected to produce SCR or HIF2a-566 were injected subcutaneously into the flanks of nude mice. Approximately 8-10 weeks later,
tumors were excised and weighed. Ten tumors per line were analyzed. Error bars = standard error of the mean. P<=0.001
according to a Mann-Whitney U statistic analysis. F. Representative photographs of tumors analyzed in Figure 1E. Left: Tumor from
cells expressing SCR; Right: Tumor from cells expressing HIF2a-566.
doi: 10.1371/journal.pone.0080544.g001
Contributions of HIF Target Genes to Kidney Cancer
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inhibits VEGF receptors and they have clearly shown positive
clinical efficacy [6]. However, although sunitinib is generally
very effective in shrinking tumors, the xenograft tumors formed
by the 786-O VHL-/- cell line tend to be only mildly responsive
to sunitinib treatment in mice [34,35], thus it raises the question
whether VEGF is critical for 786-O VHL-/- cells to grow into
tumor efficiently in mice. To address this, we identified an
shRNA construct VEGF-1137 that very efficiently suppressed
the VEGF expression below the level seen in the VHL+/+ cells
(Figure 3A). Like shRNA constructs against HIF, VEGF-1137
did not significantly change the cell growth in the petri dish
(Figure S1B in File S1). We then compared the tumor growth of
VHL-/- 786-O cells expressing a control shRNA (SCR) with that
of the same cells expressing VEGF-1137. The cells depleted of
VEGF generated much smaller tumors than the control cells in
the same mice (Figure 3B and C), suggesting that HIF-induced
VEGF expression contributed positively to the tumor growth by
VHL-/- cancer cells.
Cyclin D1 is a cell cycle regulator that promotes cell
proliferation along with many other important functions that
enhances cancer development [36]. It is also another HRG that
has been shown to play an important oncogenic role in breast
Figure 2.  Validation of HIF target genes in VHL-deficient RCC cells.  A. The mRNA levels of HIF2α in 786-O VHL+/+ and
VHL-/- cells expressing indicated plasmids or shRNA constructs were measured with real-time PCR.
B. The mRNA levels of HIF target genes in 786-O VHL+/+ and VHL-/- cells expressing indicated plasmids or shRNA constructs
were measured with real-time PCR.
doi: 10.1371/journal.pone.0080544.g002
Contributions of HIF Target Genes to Kidney Cancer
PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e80544
cancer [25]. As it is a faithful target for HIF2α in RCC cells [26],
it might also have a significant impact on RCC biology. To
investigate its role in tumor growth of kidney cancer, its
expression in VHL-/- cells were very efficiently knocked down
by CCND1-2322 (Figure 3D). CCND1-2322 did not significantly
change the cell growth in petri dish (Figure S1C in File S1).
However, these cells grew into much smaller tumors than the
cells expressing SCR (Figure 3E and F), which strongly
suggests that Cyclin D1, like VEGF, also promoted tumor
growth by the VHL-/- cancer cells in mice.
Suppression of neither ANGPTL4, EGLN3, nor
ENOLASE 2 significantly change the tumor growth
Recent discoveries revealed that ANGPTL4 was involved in
angiogenesis, altered redox regulation, and metastasis [24], so
we decided to investigate its role in kidney cancer progression.
The mRNA level of ANGPTL4 in VHL-/- cells was twice as
much as that in VHL+/+ cells, and the shRNA construct
ANGPTL4-786 canceled that increase in the VHL-/- cells
(Figure 4A). ANGPTL4-786 did not significantly change the cell
growth in petri dish (Figure S1D in File S1). ANGPTL4-786 also
failed to change the tumor growth by VHL-/- cells significantly
(Figure 4B and C).
Figure 3.  VEGF and Cyclin D1 positively contribute to tumor growth by VHL-deficient RCC cells.  A. Lysates from 786-O
cells stably expressing VHL, the SCR or the VEGF shRNAs were prepared and assayed with VEGF ELISA. B. 786-O VHL-/- cells
infected to produce SCR or VEGF-1137 were injected subcutaneously into the flanks of nude mice. Approximately 8-10 weeks later,
tumors were excised and weighed. Eight tumors per line were analyzed. Error bars = standard error of the mean. P<=0.001
according to a Mann-Whitney U statistic analysis. C. Representative photographs of tumors analyzed in Figure 3B. Left: Tumor from
cells expressing SCR; Right: Tumor from cells expressing VEGF-1137. D. Total cell lysates of 786-O cells stably expressing VHL,
the SCR or the Cyclin D1 shRNAs were immunoblotted with the indicated antibodies. E. 786-O VHL-/- cells infected to produce SCR
or CCND1-2322 were injected subcutaneously into the flanks of nude mice. Approximately 8-10 weeks later, tumors were excised
and weighed. Eight tumors per line were analyzed. Error bars = standard error of the mean. P<=0.001 according to a t-test. F.
Representative photographs of tumors analyzed in Figure 3E. Left: Tumor from cells expressing SCR; Right: Tumor from cells
expressing CCND1-2322.
doi: 10.1371/journal.pone.0080544.g003
Contributions of HIF Target Genes to Kidney Cancer
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Figure 4.  ENO2, EGLN3, and ANGPTL4 make no significant contribution to tumor growth by VHL-deficient RCC cells.  A.
The mRNA levels of ANGPTL4 in 786-O cells stably expressing VHL, the SCR or the ANGPTL4 shRNAs were analyzed with real-
time PCR. B. 786-O VHL-/- cells infected to produce SCR or ANGPTL4-786 were injected subcutaneously into the flanks of nude
mice. Approximately 8-10 weeks later, tumors were excised and weighed. Nine tumors per line were analyzed. Error bars =
standard error of the mean. P=0.255 according to a t-test. C. Representative photographs of tumors analyzed in Figure 4B. Left:
Tumor from cells expressing SCR; Right: Tumor from cells expressing ANGPTL4-786. D. The mRNA levels of EGLN3 in 786-O
cells stably expressing VHL, the SCR or the EGLN3 shRNA were analyzed with real-time PCR. E. 786-O VHL-/- cells infected to
produce SCR or EGLN3-692 were injected subcutaneously into the flanks of nude mice. Approximately 8-10 weeks later, tumors
were excised and weighed. Seven tumors per line were analyzed. Error bars = standard error of the mean. P=0.097 according to a
Mann-Whitney U statistic analysis. F. Representative photographs of tumors analyzed in Figure 4E. Left: Tumor from cells
expressing SCR; Right: Tumor from cells expressing EGLN3-692. G. The mRNA levels of ENO2 in 786-O cells stably expressing
VHL, the SCR or the ENO2 shRNAs were analyzed with real-time PCR. H. 786-O VHL-/- cells infected to produce SCR or
ENO2-1992 were injected subcutaneously into the flanks of nude mice. Approximately 8-10 weeks later, tumors were excised and
weighed. Nine tumors per line were analyzed. Error bars = standard error of the mean. P=0.176 according to a t-test. I.
Representative photographs of tumors analyzed in Figure 4H. Left: Tumor from cells expressing SCR; Right: Tumor from cells
expressing ENO2-1992.
doi: 10.1371/journal.pone.0080544.g004
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Next we examined whether EGLN3, one of the most highly
induced HRG [17,28], plays any role in tumor growth. Although
normally EGLN1 is the major proline hydroxylase for HIFα
proteins, under certain conditions EGLN3 could also modify
HIFα proteins for proteasomal degradation [37,38]. 786-O cells
have no pVHL, so even if HIFα is proline hydroxylated it would
not affect its protein stability. EGLN3 also was also reported to
have non-HIF substrates and possess HIF-independent
biological activities [29-31]. Surprisingly, the shRNA construct
EGLN3-692 that efficient suppressed the protein expression of
EGLN3 did not reduce the tumor growth (the small increase in
tumor weight after EGLN3 knockdown was not statistically
significant) (Figure 4D, E, and F). EGLN3-692 did not
significantly change the cell growth in petri dish either (Figure
S1E in File S1).
Enolase 2 (ENO2) is an enzyme that hydrolyses 2-phospho-
D-glycerate into phosphoenolpyruvate, a critical step in the
glycolysis pathway that converts glucose into pyruvate and
generates ATPs without using molecular oxygen. It was
reported that in VHL-defective kidney cancer cells the elevated
HIF activity caused the decrease of the amount and repression
of the function of mitochondria and shifted the cellular
metabolism to glycolysis [39], so we wanted to examine the
contribution of ENO2, which is critical to glycolysis, to tumor
growth. The mRNA level of ENO2 was much higher in VHL-/-
cells than that in VHL+/+ cells, and the ENO2-1992 shRNA
construct efficiently reduced its expression in VHL-/- cells
(Figure 4G), but it did not significantly change the cell growth in
petri dish (Figure S1F in File S1). We found that ENO2-1992
failed to change tumor growth significantly (Figure 4H and I).
Suppression of HIF-induced genes GLUT1 or IGFBP3
strongly enhance tumor growth
The constitutively high level of HIF activity shifts the VHL-
defective kidney cancer cells metabolism from oxidative
phosphorylation toward glycolysis to derive ATP without using
molecular oxygen [39]. However, the efficiency of ATP
generation through glycolysis is much lower than oxidative
phosphorylation, thus the cancer cells demand for glucose is
higher than that of the normal cells. To achieve that, HIF
strongly induces the expression of GLUT1, a glucose
transporter that enables the cancer cells to import glucose
efficiently. To address the importance of GLUT1 to tumor
growth, we successfully eliminated the GLUT1 expression by
stably expressing GLUT1-2310 in these cells (Figure 5A).
GLUT1-2310 did not significantly change the cell growth in petri
dish (Figure S1G in File S1). Surprisingly and contrary to the
hypothesis that GLUT1 was essential to tumor growth, its loss
actually increased tumor growth (Figure 5B and C). The
possible reasons for this observation will be discussed later.
IGFBP3 is another HRG that is highly induced by HIF and it
is known to have IGF-dependent and IGF-independent
biological functions that are important for cancer development
[33]. To examine its contribution to tumor growth, we identified
several shRNA constructs that suppressed IGFBP3 protein
expression in VHL-/- cells (Figure 5D). IGFBP3-711 was
chosen for further analysis because it was the most effective
construct. IGFBP3-711 did not significantly change the cell
growth in petri dish (Figure S1H in File S1). Interestingly,
suppression of IGFBP3 expression, instead of retarding tumor
growth, very significantly enhanced the tumor growth (Figure
5E and F).
IGF1R is tumor-promoting in 786-O VHL-/- cells
IGFBP3 belongs to a family of proteins that bind to insulin
like growth factors and either inhibit or stimulate the IGF
receptors. In order to investigate whether IGFIR activity is
affected by IGFBP3 depletion in 786-O cells, we probed the
tyrosine phosphorylation signals on IGFIR. We found that
depletion of IGFBP3 did not visibly change the tyrosine
phosphorylation signals associated with IGFIR, suggesting that
there is little change of IGFIR activity (Figure S4 in File S1).
We then sought to examine whether IGFIR plays an
oncogenic role in our model. Indeed IGFIR-1959 that effectively
reduced IGFIRβ expression very significantly reduced tumor
growth (Figure 6A, B and C). When we investigated the mutual
interaction between IGFIR and IGFBP3, we made a surprising
discovery that IGFIRβ suppression led to profound up-
regulation of the protein levels of IGFBP3 (Figure 6D). As
IGFIR-532, IGFIR-1959, and IGFIR-3475 reduced IGFIR
protein expression to various extents, and all of them caused
IGFBP3 up-regulation, this was unlikely to be an off-target side
effect of a specific shRNA construct. The measurement of
mRNA levels of IGFIR and IGFBP3 further revealed that IGFIR
loss caused the increase of IGFBP3 mRNA levels, which at
least partially explained the increases of IGFBP3 protein levels
(Figure 6E). It remains a distinct possibility that the strong
tumor suppressive effect of IGFIR loss was mostly due to the
high levels of IGFBP3. If this is the case, since IGFIR is
depleted, IGFBP3 must act in an IGFIR-independent manner.
Discussion
Although VEGF and VEGFR have been proved to be critical
targets for RCC treatment, it was surprising that whether down-
regulation of VEGF in ccRCC cells had any impact on tumor
growth was not directly tested in a xenograft system. Besides it
was discovered before that the tumors formed by 786-O cells
were relatively insensitive to VEGF inhibitor sunitinib [34,35],
so we decided to investigate whether the loss of VEGF
expression would reduce tumor growth in 786-O-derived
tumors. The positive result confirmed that VEGF expression
was still important to tumor growth, but it is not as critical as
HIF itself. The stronger effect of the shRNA than that of
sunitinib could simply be due to the relative constant effect of
shRNA while drug might fail to sufficiently inhibits its target
between doses.
As CCND1 was a critical oncogene for breast cancer, we
sought to address its importance in this model. As expected, it
also positively contributed to the tumor growth but its efficacy
was moderate compared to HIF.
Since HIF2α overexpression in VHL+/+ 786-O cells was
sufficient to generate big tumors in the xenograft model, we
wondered whether the overexpression of an HRG could do the
same. The overexpression of neither VEGF nor CCND1 in VHL
+/+ 786-O cells was able to cause robust tumor growth (data
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not shown). This was consistent with the observation from
another lab (Othon Iliopoulos, personal communication). Thus
it seems that although both VEGF and Cyclin D1 were able to
promote tumor growth, neither of which was as powerful as
HIF.
Although ANGPTL4 was reported to increase or decrease
tumor growth and angiogenesis depending on the cancer types
[24], it did not seem to be a major player in this model as its
efficient suppression did not alter how fast the tumors grew.
EGLN3 was found to be among the most highly induced HRGs,
and it is known that it can biochemically hydroxylate key proline
residues on the HIFα proteins [38] and its depletion led to
HIF2α stabilization [37]. Since in 786-O cells the VHL protein is
absent, this would not lead to the destruction of HIFα protein
and did not obviously change the transcriptional activity of HIF.
It is also known that EGLN3 has other hydroxylase targets
[29,30] and have HIF-dependent and HIF-independent
biological activities [31], so we wondered whether EGLN3 loss
would have any impact on tumor growth. The VHL-/- 786-O
cells depleted of EGLN3 grew tumors just as well as the control
cells, suggesting that EGLN3 inhibition alone is not a good way
to suppress kidney tumor growth. Similarly, suppression of
ENO2 expression did not slow down the tumor growth. Either
its function is not critical for tumor growth, or the remaining
ENO1, or another activated compensatory pathway
circumvents the loss of ENO2 protein.
It was totally unexpected that the suppression of GLUT1
enhanced, instead of suppressed, the tumor growth. This
seemed to disagree with a report that a class of compound,
exemplified by STF-31, could directly bind and inhibit GLUT1
function and selectively kill VHL-deficient RCC cancer cells
[40]. It was further revealed that the STF-31 inhibited glucose
Figure 5.  GLUT1 and IGFBP3 are tumor suppressive HRGs in 786-O cells.  A. Lysates from 786-O cells stably expressing VHL,
the SCR or the GLUT1 shRNAs were prepared and immunoblotted with indicated antibodies. B. 786-O VHL-/- cells infected to
produce SCR or GLUT1-2310 were injected subcutaneously into the flanks of nude mice. Approximately 8-10 weeks later, tumors
were excised and weighed. Eight tumors per line were analyzed. Error bars = standard error of the mean. P<=0.001 according to a
Mann-Whitney U statistic analysis. C. Representative photographs of tumors analyzed in Figure 5B. Left: Tumor from cells
expressing SCR; Right: Tumor from cells expressing GLUT1-2310. D. Total cell lysates of 786-O cells stably expressing VHL, the
SCR or the IGFBP3 shRNAs were immunoblotted with the indicated antibodies. E. 786-O VHL-/- cells infected to produce SCR or
IGFBP3-711 were injected subcutaneously into the flanks of nude mice. Approximately 8-10 weeks later, tumors were excised and
weighed. Ten tumors per line were analyzed. Error bars = standard error of the mean. P<=0.001 according to a Mann-Whitney U
statistic analysis. F. Representative photographs of tumors analyzed in Figure 5E. Left: Tumor from cells expressing SCR; Right:
Tumor from cells expressing IGFBP3-711.
doi: 10.1371/journal.pone.0080544.g005
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Figure 6.  IGFIR loss suppresses tumor growth by VHL-defective RCC cells.  A. Lysates from 786-O VHL-/- cells expressing
SCR or an IGFIR shRNA were immunoblotted with indicated antibodies. B. 786-O VHL-/- cells infected to produce the SCR or
IGFIR-1959 were injected subcutaneously into the flanks of nude mice. Approximately 9 weeks later, tumors were excised and
weighed. Six tumors per line were analyzed. Error bars = standard error of the mean. P=0.002 according to a Mann-Whitney U
statistic analysis. C. Representative photographs of nude mice and tumors analyzed in Figure 6B. Left: Tumor from cells expressing
SCR; Right: Tumor from cells expressing IGFIR-1959. D. Lysates from 786-O VHL-/- cells expressing SCR or IGFIR shRNAs were
immunoblotted with indicated antibodies. E. The mRNA levels of IGFIR and IGFBP3 in 786-O VHL-/- cells expressing SCR or IGFIR
shRNAs were analyzed with real-time PCR. F. A model depicting how HIF and HRGs regulate tumor growth in ccRCC.
doi: 10.1371/journal.pone.0080544.g006
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uptake, significantly reduced ATP synthesis, led to cell death
and inhibited tumor growth in xenograft models [40]. But a
major difference exists between our studies: we only
suppressed GLUT1 expression, while STF-31 potentially could
inhibit all glucose transporter’s activity. Since GLUT1, GLUT2,
GLUT3, GLUT4 are all expressed at different levels in RCC
and they are all capable of transporting glucose [40], it is highly
possible that in our system the loss of GLUT1 led to
compensatory up-regulation of another glucose transporter
which led to worse outcome, while STF-31 was able to inhibit
the whole family of glucose transporters to inhibit tumor growth.
Indeed in RCC4 VHL+/+ cells where the GLUT1 expression
was much lower than that in the RCC4 VHL-/- cells, the GLUT2
level in the VHL+/+ cells was much higher than that in the
VHL-/- cells, presumably due to a compensatory mechanism
[40]. Whatever the explanation, our result indicates that the
inhibition of GLUT1 alone is highly unlikely to be a successful
therapeutic strategy against RCC, while the ability to inhibit all
glucose transporters might be the key to achieve clinical
efficacy.
Our previous finding that the suppression of JARID1C, an
HRG, actually enhanced tumor growth suggested the existence
of other tumor-inhibitory HRGs [41]. We found that the
suppression of IGFBP3 very significantly increased the tumor
growth, suggesting that it is another potent tumor-inhibitory
HRG. As it binds to IGF which is an activator of IGFIR, a known
oncogene in many types of human cancer cells [42], we
investigated IGFIR activation status after IGFBP3 depletion. No
obvious activation of IGFIR was discovered, suggesting its
tumor-inhibitory activity might be IGFIR independent. We
further investigated whether IGFIR suppression did reduce
tumor growth, and the result confirmed that the expression of
IGFIR was essential for efficient tumor growth. Surprisingly,
loss of IGFIR increased both the mRNA level, and to a greater
extent, the protein level of IGFBP3, further suggesting that the
elevated IGFBP3 might be capable of suppressing tumor
growth in the absence of IGFIR. As IGFBP3 were reported to
interact with TGF-β pathway [43,44], increase the ratio of
apoptotic (Bax and Bad) to the anti-apoptotic proteins (Bcl2
and Bcl-XL) [45], inhibit NF-κB activity [46], its abilities to
inhibits cell growth/promotes apoptosis in an IGFIR-
independent manner were well documented and might be at
play here [33]. So IGFIR could be a very good drug target in
addition to VEGFR in RCC, and any event that significantly
enhances IGFBP3 expression might be desirable when treating
RCC.
Our results indicate that there might be other HRGs that
mediate the critical oncogenic activity of HIF in RCC, as VEGF
or Cyclin D1 overexpression failed to drive efficient tumor
growth in VHL+/+ cells as the overexpression of HIF2α did.
However, it is also possible that the combined effects of many
tumor-promoting HRGs, including VEGF and Cyclin D1, were
responsible for the tumor-inducing power of HIF (Figure 6F). It
is an open question whether the overexpression of a single
HRG is capable of driving efficient tumor growth in VHL+/+
786-O cells as HIF2α could. To further complicate the matter,
the contributions of HIF-induced microRNAs might also be
important as well, and further research might reveal whether
one or more HRGs or microRNAs, in addition to VEGF and
other important HRGs, might channel the major oncogenic
activity of HIF that can be targeted for efficient therapeutic
intervention in RCC.
Supporting Information
Table S1.  The list of the primers used for real-time PCR
experiments in this paper.
(DOCX)
File S1.  File includes Figures S1, S2, S3, and S4. Figure
S1. VHL status or change of HRG expression in 786-O cells
does not alter in vitro growth rates. 786-O VHL+/+, 786-O
VHL-/- cells (A), 786-O VHL-/- cells expressing either control
shRNA (SCR) or VEGF-1137 (B), CCND1-2322 (C),
ANGPTL4-786 (D), EGLN3-692 (E), ENO2-1992 (F),
GLUT1-2310 (G), IGFBP3-711 (H) were used to compare in
vitro proliferation rates. Figure S2. 786-O cells with the HIF1β
depleted have diminished expression of the HRG GLUT1. 786-
O VHL-/- cells expressing either SCR or HIF1b-1770 were
either untreated or treated with hypoxia mimetics DFO or CoCl2
overnight. The cells were washed, lysed and subjected to
western blots with indicated antibodies. Figure S3. The
confirmation of HRGs in 786-O cells. Total RNAs were
extracted from 786-O VHL+/+, 786-O VHL-/- cells, 786-O
VHL-/- cells expressing two shRNA constructs against HIF2α,
and 786-O VHL+/+ cells expressing either a functional HIF2α
mutant or a non-functional HIF2α mutant. First strand cDNA
was generated from these samples then analyzed by real-time
PCR for the indicated genes of interest. Figure S4. IGFBP3
suppression does not lead to increase of tyrosine
phosphorylation on IGFIR in 786-O cells. Lysates from 786-O
cell stably expressing either SCR or IGFBP3 shRNAs were
used for immunoprecipitation of IGFIRβ. The
immunoprecipitates were immunoblotted with indicated
antibodies.
(TIF)
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